CY1121832T1 - Μονοκλωνικα αντισωματα κατα του παραγοντα αναπτυξεως και διαφοροποιησεως 15(gdf-15) - Google Patents

Μονοκλωνικα αντισωματα κατα του παραγοντα αναπτυξεως και διαφοροποιησεως 15(gdf-15)

Info

Publication number: CY1121832T1
Authority: CY; Cyprus
Prior art keywords: monoclonal antibodies; gdf; antibodies against; differentiation factor; against growth
Prior art date: 2012-09-26

Application number

CY20191100787T

Other languages

Greek (el)

English (en)

Inventor

Jörg WISCHHUSEN

Markus JUNKER

Thomas Müller

Stefan SAREMBA

Original Assignee

Julius-Maximilians-Universität Würzburg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-26

Filing date

2019-07-24

Publication date

2020-07-31

2019-07-24 Application filed by Julius-Maximilians-Universität Würzburg filed Critical Julius-Maximilians-Universität Würzburg

2020-07-31 Publication of CY1121832T1 publication Critical patent/CY1121832T1/el

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)

CY20191100787T 2012-09-26 2019-07-24 Μονοκλωνικα αντισωματα κατα του παραγοντα αναπτυξεως και διαφοροποιησεως 15(gdf-15) CY1121832T1 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP12186185		2012-09-26
EP13776433.8A EP2900263B1 (en)	2012-09-26	2013-09-26	Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
PCT/EP2013/070127 WO2014049087A1 (en)	2012-09-26	2013-09-26	Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)

Publications (1)

Publication Number	Publication Date
CY1121832T1 true CY1121832T1 (el)	2020-07-31

Family

ID=46888333

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY20191100787T CY1121832T1 (el)	2012-09-26	2019-07-24	Μονοκλωνικα αντισωματα κατα του παραγοντα αναπτυξεως και διαφοροποιησεως 15(gdf-15)

Country Status (23)

Country	Link
US (5)	US20150239968A1 (sr)
EP (2)	EP2900263B1 (sr)
JP (4)	JP2015532271A (sr)
KR (1)	KR101838786B1 (sr)
CN (1)	CN104853775B (sr)
AU (2)	AU2013322628B2 (sr)
CA (1)	CA2886207C (sr)
CY (1)	CY1121832T1 (sr)
DK (1)	DK2900263T3 (sr)
ES (1)	ES2742287T3 (sr)
HR (1)	HRP20191326T1 (sr)
HU (1)	HUE044363T2 (sr)
IL (2)	IL237828B (sr)
LT (1)	LT2900263T (sr)
NZ (1)	NZ706189A (sr)
PL (1)	PL2900263T3 (sr)
PT (1)	PT2900263T (sr)
RS (1)	RS59045B1 (sr)
SG (1)	SG11201502279YA (sr)
SI (1)	SI2900263T1 (sr)
SM (1)	SMT201900457T1 (sr)
TR (1)	TR201910744T4 (sr)
WO (1)	WO2014049087A1 (sr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS59045B1 (sr) *	2012-09-26	2019-08-30	Univ Wuerzburg J Maximilians	Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15)
ES2902533T3 (es)	2013-11-21	2022-03-28	Brigham & Womens Hospital Inc	Composiciones y métodos para tratar la hipertensión pulmonar
GB2524552B (en) *	2014-03-26	2017-07-12	Julius-Maximilians-Universitãt Wurzburg	Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
RS59700B1 (sr) *	2014-03-26	2020-01-31	Univ Wuerzburg J Maximilians	Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera
GB2524553C (en) *	2014-03-26	2017-07-19	Julius-Maximilians-Universitãt Würzburg	Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
AU2015276800B2 (en) *	2014-06-20	2021-03-04	Aveo Pharmaceuticals, Inc.	Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator
EP3174550B1 (en) *	2014-08-01	2020-01-29	The Brigham and Women's Hospital, Inc.	Methods and compositions relating to treatment of pulmonary arterial hypertension
FI3356827T3 (fi)	2015-10-02	2024-01-03	Univ Wuerzburg J Maximilians	GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
CN108463246B (zh)	2015-10-02	2025-02-28	尤利乌斯·马克西米利安维尔茨堡大学	使用人生长分化因子15(gdf-15)抑制剂和免疫检查点阻断剂的联合治疗
GB201517528D0 (en) *	2015-10-02	2015-11-18	Julius Maximillians Universitãt Würzburg	GDF-15 as a diagnosis marker for melanoma
ITUB20154769A1 (it) *	2015-11-04	2017-05-04	Centro Di Riferimento Oncologico Cro Irccs Aviano	Anticorpo monoclonale anti-BARF1
WO2017150314A1 (ja) *	2016-02-29	2017-09-08	公立大学法人横浜市立大学	去勢抵抗性前立腺癌を検出する方法及び検出試薬
US20170299608A1 (en) *	2016-03-04	2017-10-19	Ngm Biopharmaceuticals, Inc.	Compositions and methods for modulating body weight
MY194669A (en)	2016-03-31	2022-12-12	Ngm Biopharmaceuticals Inc	Binding Proteins and Methods of use Thereof
WO2017189724A1 (en) *	2016-04-27	2017-11-02	Novartis Ag	Antibodies against growth differentiation factor 15 and uses thereof
CN107782900A (zh) *	2016-08-31	2018-03-09	朱海燕	人生长分化因子‑15的检测试纸组件
KR102010652B1 (ko) *	2017-08-21	2019-08-13	서울대학교병원	간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
WO2021111636A1 (ja) *	2019-12-06	2021-06-10	大塚製薬株式会社	抗ｇｄｆ１５抗体
KR20230107309A (ko)	2020-11-10	2023-07-14	카탈임 게엠베하	항-gdf15 항체 및 암 치료용 투여 용법
CN112698042A (zh) *	2020-12-17	2021-04-23	北京赛诺浦生物技术有限公司	检测人生长分化因子-15的荧光免疫层析试纸条及其制备方法和应用
US20240182585A1 (en)	2021-03-31	2024-06-06	Cambridge Enterprise Limited	Therapeutic inhibitors of gdf15 signalling
CN113252905A (zh) *	2021-05-12	2021-08-13	北京赛诺浦生物技术有限公司	人生长分化因子-15磁微粒化学发光检测试剂盒及其应用
IL310535A (en)	2021-08-10	2024-03-01	Byomass Inc	Anti-gdf15 antibodies, compositions and uses thereof
CN113702647B (zh) *	2021-08-31	2024-03-15	普十生物科技(北京)有限公司	人生长分化因子15即时检测试剂盒、其制备方法及其应用
WO2023122213A1 (en)	2021-12-22	2023-06-29	Byomass Inc.	Targeting gdf15-gfral pathway cross-reference to related applications
CN119487065A (zh) *	2022-05-09	2025-02-18	舒泰神（北京）生物制药股份有限公司	特异性识别gdf15的抗体及其应用
CN116813742A (zh) *	2022-11-22	2023-09-29	杭州博茵生物技术有限公司	人gdf-15抗原表位肽、抗原、抗体、试剂盒及应用
CN116462757A (zh) *	2023-03-24	2023-07-21	科兴生物制药股份有限公司	Gdf15的单域抗体及其应用
CN118515761B (zh) *	2024-07-19	2024-10-29	北京志道生物科技有限公司	一种gdf-15纳米抗体及其应用
CN118878677A (zh) *	2024-09-29	2024-11-01	江苏凯基生物技术股份有限公司	一种IgM亚型单克隆抗体及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5595756A (en) *	1993-12-22	1997-01-21	Inex Pharmaceuticals Corporation	Liposomal compositions for enhanced retention of bioactive agents
US6455677B1 (en)	1998-04-30	2002-09-24	Boehringer Ingelheim International Gmbh	FAPα-specific antibody with improved producibility
US6465181B2 (en)	1999-03-25	2002-10-15	Abbott Laboratories	Reagents and methods useful for detecting diseases of the prostate
JP2002543841A (ja)	1999-05-17	2002-12-24	バイオファームゲゼルシャフトツアバイオテクノロジシェンエントヴィックルングウントツムフェルトリーブフォンファルマカエムベーハー	ＴＧＦ−βスーパーファミリーの新規のメンバーであるＧＤＦ―１５の神経保護特性
AU2001288770A1 (en)	2000-09-08	2002-03-22	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
SI2311873T1 (sl)	2004-01-07	2018-12-31	Novartis Vaccines And Diagnostics, Inc.	M-CSF-specifična monoklonska protitelesa in njihova uporaba
EP2441466B1 (en)	2004-04-13	2014-07-23	St Vincent's Hospital Sydney Limited	MIC-1 inhibiting agent
US20100278843A1 (en)	2007-08-16	2010-11-04	St. Vincent's Hospital Sydney Limited	Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN101896192A (zh)	2007-10-09	2010-11-24	圣文森特医院悉尼有限公司	一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法
NZ591484A (en)	2008-09-29	2012-09-28	Roche Glycart Ag	Antibodies against human il 17 and uses thereof
US20120309697A1 (en)	2009-10-28	2012-12-06	Samuel Norbert Breit	Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) *	2010-03-03	2015-12-15	Detroit R & D, Inc.	Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
CN101852804B (zh) *	2010-03-29	2013-06-12	中国医学科学院病原生物学研究所	Gdf15蛋白的抗体的新用途
TWI452136B (zh) *	2010-11-17	2014-09-11	中外製藥股份有限公司	A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) *	2011-07-21	2014-07-29	Zoetis Llc	Interleukin-31 monoclonal antibody
CN102321173B (zh) *	2011-08-12	2013-04-03	中国医学科学院肿瘤研究所	人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en)	2011-08-31	2013-03-06	VTU Holding GmbH	Protein expression
EP3683228A3 (en)	2012-01-26	2020-07-29	Amgen Inc.	Growth differentiation factor 15 (gdf-15) polypeptides
RS59045B1 (sr)	2012-09-26	2019-08-30	Univ Wuerzburg J Maximilians	Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15)
ES2791183T3 (es)	2012-12-21	2020-11-03	Aveo Pharmaceuticals Inc	Anticuerpos anti-GDF15
FI3356827T3 (fi) *	2015-10-02	2024-01-03	Univ Wuerzburg J Maximilians	GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
CN108463246B (zh) *	2015-10-02	2025-02-28	尤利乌斯·马克西米利安维尔茨堡大学	使用人生长分化因子15(gdf-15)抑制剂和免疫检查点阻断剂的联合治疗
CN112912395B (zh) *	2018-08-20	2024-08-23	辉瑞公司	抗gdf15抗体、组合物和使用方法

2013
- 2013-09-26 RS RS20190923A patent/RS59045B1/sr unknown
- 2013-09-26 HR HRP20191326 patent/HRP20191326T1/hr unknown
- 2013-09-26 PL PL13776433T patent/PL2900263T3/pl unknown
- 2013-09-26 ES ES13776433T patent/ES2742287T3/es active Active
- 2013-09-26 EP EP13776433.8A patent/EP2900263B1/en active Active
- 2013-09-26 AU AU2013322628A patent/AU2013322628B2/en active Active
- 2013-09-26 CN CN201380061148.XA patent/CN104853775B/zh active Active
- 2013-09-26 SG SG11201502279YA patent/SG11201502279YA/en unknown
- 2013-09-26 LT LTEP13776433.8T patent/LT2900263T/lt unknown
- 2013-09-26 SM SM20190457T patent/SMT201900457T1/it unknown
- 2013-09-26 EP EP19177843.0A patent/EP3590537A1/en active Pending
- 2013-09-26 US US14/431,281 patent/US20150239968A1/en not_active Abandoned
- 2013-09-26 JP JP2015533588A patent/JP2015532271A/ja active Pending
- 2013-09-26 WO PCT/EP2013/070127 patent/WO2014049087A1/en not_active Ceased
- 2013-09-26 HU HUE13776433 patent/HUE044363T2/hu unknown
- 2013-09-26 NZ NZ706189A patent/NZ706189A/en unknown
- 2013-09-26 PT PT13776433T patent/PT2900263T/pt unknown
- 2013-09-26 SI SI201331512T patent/SI2900263T1/sl unknown
- 2013-09-26 TR TR2019/10744T patent/TR201910744T4/tr unknown
- 2013-09-26 KR KR1020157010334A patent/KR101838786B1/ko active Active
- 2013-09-26 DK DK13776433.8T patent/DK2900263T3/da active
- 2013-09-26 CA CA2886207A patent/CA2886207C/en active Active
2015
- 2015-03-19 IL IL237828A patent/IL237828B/en active IP Right Grant
2017
- 2017-05-26 AU AU2017203523A patent/AU2017203523B2/en active Active
- 2017-07-31 JP JP2017147489A patent/JP6670275B2/ja active Active
2018
- 2018-03-12 US US15/918,841 patent/US10781251B2/en active Active
2019
- 2019-07-24 CY CY20191100787T patent/CY1121832T1/el unknown
- 2019-10-24 JP JP2019193124A patent/JP7270522B2/ja active Active
2020
- 2020-08-11 US US16/990,929 patent/US11891436B2/en active Active
- 2020-09-16 IL IL277392A patent/IL277392A/en unknown
2021
- 2021-08-11 JP JP2021131153A patent/JP2022017219A/ja active Pending
2023
- 2023-12-21 US US18/392,926 patent/US20240239882A1/en active Pending
2025
- 2025-09-24 US US19/338,643 patent/US20260116961A1/en active Pending

Also Published As

Publication number	Publication date
CA2886207C (en)	2021-01-05
US20210054060A1 (en)	2021-02-25
JP6670275B2 (ja)	2020-03-18
EP3590537A1 (en)	2020-01-08
US20150239968A1 (en)	2015-08-27
DK2900263T3 (da)	2019-07-29
IL237828B (en)	2020-10-29
SG11201502279YA (en)	2015-04-29
EP2900263A1 (en)	2015-08-05
HUE044363T2 (hu)	2019-10-28
JP2015532271A (ja)	2015-11-09
CA2886207A1 (en)	2014-04-03
AU2013322628B2 (en)	2017-03-02
US20180305447A1 (en)	2018-10-25
CN104853775A (zh)	2015-08-19
BR112015006829A2 (pt)	2017-11-21
US11891436B2 (en)	2024-02-06
US20260116961A1 (en)	2026-04-30
HK1210950A1 (en)	2016-05-13
AU2017203523A1 (en)	2017-06-15
JP2018019690A (ja)	2018-02-08
PL2900263T3 (pl)	2019-10-31
JP7270522B2 (ja)	2023-05-10
RS59045B1 (sr)	2019-08-30
SI2900263T1 (sl)	2019-09-30
ES2742287T3 (es)	2020-02-13
WO2014049087A1 (en)	2014-04-03
JP2022017219A (ja)	2022-01-25
AU2013322628A1 (en)	2015-04-09
HRP20191326T1 (hr)	2019-11-01
IL277392A (en)	2020-11-30
JP2020043855A (ja)	2020-03-26
IL237828A0 (en)	2015-05-31
US20240239882A1 (en)	2024-07-18
TR201910744T4 (tr)	2019-08-21
SMT201900457T1 (it)	2019-11-13
CN104853775B (zh)	2023-10-20
US10781251B2 (en)	2020-09-22
NZ706189A (en)	2016-09-30
EP2900263B1 (en)	2019-06-05
PT2900263T (pt)	2019-07-29
LT2900263T (lt)	2019-10-10
KR20150082229A (ko)	2015-07-15
AU2017203523B2 (en)	2019-02-07
KR101838786B1 (ko)	2018-03-15

Publication	Publication Date	Title
CY1121832T1 (el)	2020-07-31	Μονοκλωνικα αντισωματα κατα του παραγοντα αναπτυξεως και διαφοροποιησεως 15(gdf-15)
CY1120471T1 (el)	2019-07-10	Αντισωματα κατα του cd70
MX356337B (es)	2018-05-23	Anticuerpos contra csf-1r humano y sus usos.
MX336682B (es)	2016-01-27	Anticuerpos contra csf-1r humanos y usos de los mismos.
CY1125697T1 (el)	2024-02-16	Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
CY1122456T1 (el)	2021-01-27	Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
CY1117563T1 (el)	2017-04-26	Αντισωματα κατα her3 και χρησεις αυτων
MX2016008098A (es)	2017-01-11	Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
CY1123145T1 (el)	2021-10-29	Anti-cd40 αντισωματα
TW201129381A (en)	2011-09-01	Antibodies against human CSF-1R and uses thereof
SG178886A1 (en)	2012-04-27	Humanized anti-cdcp1 antibodies
CY1120398T1 (el)	2019-07-10	Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
CY1119445T1 (el)	2018-03-07	Αντισωματα εναντι του ανθρωπινου gdf8
MX374291B (es)	2025-03-06	Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
TN2013000378A1 (en)	2015-01-20	Anti - sclerostin antibody crystals and formulations thereof
PH12014502010A1 (en)	2014-11-24	Bispecific antibodies against human tweak and human il17 and uses thereof
AU2014247175A8 (en)	2016-04-14	Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
EA201391175A1 (ru)	2014-07-30	Гетеродимерные иммуноглобулины
EA201400875A1 (ru)	2015-01-30	Антитела к cd47 и способы их применения
TN2015000396A1 (en)	2017-01-03	Antibody drug conjugates
CY1115030T1 (el)	2016-12-14	Διειδικα αντι-vegf/αντι-ang-2 αντισωματα
MX342034B (es)	2016-09-12	Proteinas monovalentes que se unen a antigenos.
MX340558B (es)	2016-07-14	Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
MX347020B (es)	2017-04-06	Anticuerpo contra el csf-1r.
WO2014163714A3 (en)	2015-11-26	Antibody drug conjugates